
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
The American Journal of Managed Care
over 26 years ago
Cost and Quality under Managed Care: Irreconcilable Differences?over 26 years ago
The Cost of Productivity Losses Associated with Allergic Rhinitisover 26 years ago
Current Concepts in the Management of Smoking Cessation: A Review





